The Role of Echocardiography for Diagnosis and Prognostic Stratification in Hypertrophic Cardiomyopathy

Overview

Journal J Echocardiogr

Specialties Cardiology & Vascular Diseases
Radiology

Date 2020 Apr 18

PMID 32301048

Citations 12

Authors

Leonard Mandes

Monica Rosca

Daniela Ciuperca

Bogdan A Popescu

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most frequent cardiac disease with genetic substrate, affecting about 0.2-0.5% of the population. While most of the patients with HCM have a relatively good prognosis, some are at increased risk of adverse events. Identifying such patients at risk is important for optimal treatment and follow-up. While clinical and electrocardiographic information plays an important role, echocardiography remains the cornerstone in assessing patients with HCM. In this review, we discuss the role of echocardiography in diagnosing HCM, the key features that differentiate HCM from other diseases and the use of echocardiography for risk stratification in this setting (risk of sudden cardiac death, heart failure, atrial fibrillation and stroke). The use of modern echocardiographic techniques (deformation imaging, 3D echocardiography) refines the diagnosis and prognostic assessment of patients with HCM. The echocardiographic data need to be integrated with clinical data and other information, including cardiac magnetic resonance, especially in challenging cases or when there is incomplete information, for the optimal management of these patients.

Citing Articles

Prognosis of pulmonary hypertension in patients with hypertrophic cardiomyopathy: A multicenter propensity score matching study.

Ma H, Xu F, Liu L, Kong H, Luo R, Liu M Int J Cardiol Heart Vasc. 2025; 56:101605.

PMID: 39897413 PMC: 11783049. DOI: 10.1016/j.ijcha.2025.101605.

HCM-Echo-VAR-Ensemble: Deep Ensemble Fusion to Detect Hypertrophic Cardiomyopathy in Echocardiograms.

Almadani A, Sarwar A, Agu E, Ahluwalia M, Kpodonu J IEEE Open J Eng Med Biol. 2024; 6:193-201.

PMID: 39698121 PMC: 11655110. DOI: 10.1109/OJEMB.2024.3486541.

Realistic Aspects of Cardiac Ultrasound in Rats: Practical Tips for Improved Examination.

Silva J, Azevedo T, Ginja M, Oliveira P, Duarte J, Faustino-Rocha A J Imaging. 2024; 10(9).

PMID: 39330439 PMC: 11433567. DOI: 10.3390/jimaging10090219.

Echocardiography in the Diagnosis of Cardiomyopathies: Current Status and Future Directions.

Trasca L, Popescu M, Popescu A, Balanescu S Rev Cardiovasc Med. 2024; 23(8):280.

PMID: 39076629 PMC: 11266959. DOI: 10.31083/j.rcm2308280.

Multidisciplinary approach in cardiomyopathies: From genetics to advanced imaging.

Santoro F, Vitale E, Ragnatela I, Cetera R, Leopzzi A, Mallardi A Heart Fail Rev. 2023; 29(2):445-462.

PMID: 38041702 DOI: 10.1007/s10741-023-10373-8.

References

Tower-Rader A, Mohananey D, To A, Lever H, Popovic Z, Desai M . Prognostic Value of Global Longitudinal Strain in Hypertrophic Cardiomyopathy: A Systematic Review of Existing Literature. JACC Cardiovasc Imaging. 2018; 12(10):1930-1942. DOI: 10.1016/j.jcmg.2018.07.016. View

Kitaoka H, Kubo T, Okawa M, Takenaka N, Sakamoto C, Baba Y . Tissue doppler imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2011; 24(9):1020-5. DOI: 10.1016/j.echo.2011.05.009. View

Bos J, Towbin J, Ackerman M . Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009; 54(3):201-11. DOI: 10.1016/j.jacc.2009.02.075. View

Chang S, Kim H, Lee S, Kim E, Hahm S, Kwon O . Assessment of left ventricular mass in hypertrophic cardiomyopathy by real-time three-dimensional echocardiography using single-beat capture image. J Am Soc Echocardiogr. 2013; 26(4):436-42. DOI: 10.1016/j.echo.2012.12.015. View

Maron B, Olivotto I, Bellone P, Conte M, Cecchi F, Flygenring B . Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39(2):301-7. DOI: 10.1016/s0735-1097(01)01727-2. View

Rowin E, Maron B, Haas T, Garberich R, Wang W, Link M . Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017; 69(7):761-773. DOI: 10.1016/j.jacc.2016.11.063. View

Hardarson T, de la Calzada C, Curiel R, Goodwin J . Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet. 1973; 2(7844):1462-7. DOI: 10.1016/s0140-6736(73)92730-x. View

Soler R, Mendez C, Rodriguez E, Barriales R, Ochoa J, Monserrat L . Phenotypes of hypertrophic cardiomyopathy. An illustrative review of MRI findings. Insights Imaging. 2018; 9(6):1007-1020. PMC: 6269344. DOI: 10.1007/s13244-018-0656-8. View

MacArthur D, Manolio T, Dimmock D, Rehm H, Shendure J, Abecasis G . Guidelines for investigating causality of sequence variants in human disease. Nature. 2014; 508(7497):469-76. PMC: 4180223. DOI: 10.1038/nature13127. View

10.

Nistri S, Olivotto I, Betocchi S, Losi M, Valsecchi G, Pinamonti B . Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol. 2006; 98(7):960-5. DOI: 10.1016/j.amjcard.2006.05.013. View

11.

Hoigne P, Attenhofer Jost C, Duru F, Oechslin E, Seifert B, Widmer U . Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Cardiol. 2005; 111(3):413-22. DOI: 10.1016/j.ijcard.2005.08.023. View

12.

Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu B, DAndrea A . Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015; 16(3):280. DOI: 10.1093/ehjci/jeu291. View

13.

Kato T, Noda A, Izawa H, Yamada A, Obata K, Nagata K . Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation. 2004; 110(25):3808-14. DOI: 10.1161/01.CIR.0000150334.69355.00. View

14.

Spirito P, Autore C, Formisano F, Assenza G, Biagini E, Haas T . Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014; 113(9):1550-5. DOI: 10.1016/j.amjcard.2014.01.435. View

15.

Serra W, Marziliano N . Role of cardiac imaging in Anderson-Fabry cardiomyopathy. Cardiovasc Ultrasound. 2019; 17(1):1. PMC: 6345038. DOI: 10.1186/s12947-019-0151-5. View

16.

Rowin E, Hausvater A, Link M, Abt P, Gionfriddo W, Wang W . Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017; 136(25):2420-2436. DOI: 10.1161/CIRCULATIONAHA.117.029267. View

17.

Rowin E, Maron B, Olivotto I, Maron M . Role of Exercise Testing in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2017; 10(11):1374-1386. DOI: 10.1016/j.jcmg.2017.07.016. View

18.

Severino S, Caso P, Galderisi M, De Simone L, Petrocelli A, de Divitiis O . Use of pulsed Doppler tissue imaging to assess regional left ventricular diastolic dysfunction in hypertrophic cardiomyopathy. Am J Cardiol. 1998; 82(11):1394-8. DOI: 10.1016/s0002-9149(98)00648-1. View

19.

Spirito P, BELLONE P, Harris K, Bernabo P, Bruzzi P, Maron B . Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 342(24):1778-85. DOI: 10.1056/NEJM200006153422403. View

20.

Gray B, Ingles J, Semsarian C . Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. Int J Cardiol. 2011; 152(2):258-9. DOI: 10.1016/j.ijcard.2011.07.095. View